<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The rationale of the present study was to radiolabel rituximab with 99m-<z:chebi fb="1" ids="33353">technetium</z:chebi> and to image B lymphocytes infiltration in the affected tissues of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, in particular, the candidates to be treated with unlabelled rituximab, in order to provide a rationale for 'evidence-based' therapy </plain></SENT>
<SENT sid="1" pm="."><plain>PROCEDURES: Rituximab was labelled with (99m)Tc via 2-ME reduction method </plain></SENT>
<SENT sid="2" pm="."><plain>In vitro quality controls of (99m)Tc-rituximab included stability assay, cysteine challenge, <z:chebi fb="26" ids="8984">SDS</z:chebi>-PAGE, immunoreactive fraction assay and competitive binding assay on CD20+ve Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-derived cells </plain></SENT>
<SENT sid="3" pm="."><plain>For the human pilot study, 350-370 MBq (100 μg) of (99m)Tc-rituximab were injected in 20 patients with different <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Whole body anteroposterior planar scintigraphic images were acquired 6 and 20 h p.i </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Rituximab was labelled to a high labelling efficiency (&gt;98%) and specific activity (3515-3700 MBq/mg) with retained biochemical integrity, stability and biological activity </plain></SENT>
<SENT sid="6" pm="."><plain>Scintigraphy with (99m)Tc-rituximab in patients showed a rapid and persistent spleen uptake, and the kidney appeared to be a prominent source for the excretion of radioactivity </plain></SENT>
<SENT sid="7" pm="."><plain>Inflamed joints showed a variable degree of uptake at 6 h p.i. in patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> indicating patient variability; similarly, the salivary and lacrimal glands showed variable uptake in patients with <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren's syndrome</z:e>, <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease and <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">Inflammatory disease</z:e> with particular characteristics showed specific uptake in inflammatory lesions, such as, <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatopolymyositis</z:e> patients showed moderate to high skin uptake, a <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> patient showed moderate lung uptake, a <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patient showed high oral mucosa uptake and a <z:e sem="disease" ids="C0747733" disease_type="Disease or Syndrome" abbrv="">polychondritis</z:e> patient showed moderate uptake in neck cartilages </plain></SENT>
<SENT sid="9" pm="."><plain>In one patient with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, we did not find any non-physiological uptake </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Rituximab can be efficiently labelled with (99m)Tc with high labelling efficiency </plain></SENT>
<SENT sid="11" pm="."><plain>The results suggest that this technique might be used to assess B lymphocyte infiltration in affected organs in patients with <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>; this may provide a rationale for anti-CD20 therapies </plain></SENT>
</text></document>